Intervention not reported
Adverse events, any (endpoints fall between 1 6 six months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
- no estimate extracted3 studies · 300 participantsModerate
Findings
What do systematic reviews say?
12 questions · 12 findings · 3 reviews · Developmental, Psychosocial and Learning Problems · Headline outcomes only
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 16.7%Low 5 · 41.7%Moderate 5 · 41.7%High 0 · 0%
Atypical antipsychotics vs placebo
Irritability · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
- Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes onlyno estimate extracted12 studies · 973 participantsModerate
Atypical antipsychotics vs placebo
Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
- Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 77 participantsVery low
Atypical antipsychotics vs placebo
Self‐injury · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
- Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 30 participantsLow
Atypical antipsychotics vs placebo
Adverse effects (AEs) · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
Atypical antipsychotics may leads to higher adverse effects (AEs) compared with placebo (low certainty).
1 finding from 1 review
- Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes onlyRR 4.1911 studies · 974 participantsLow
Intervention not reported
Identification of IPV by type of healthcare setting ‐ Antenatal clinics · women attending healthcare settings for any health‐related reason
1 finding from 1 review
- Screening women for intimate partner violence in healthcare settings 2015 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 663 participantsModerate
Intervention not reported
Aggression OAS, OAS‐M, MOAS, self‐reported incidents, CPRS subscale (endpoints fall between 2 weeks and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
- no estimate extracted12 studies · 606 participantsModerate
Intervention not reported
Impulsivity Q‐sort, Porteus Maze Test (endpoints fall between 2 weeks and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
- no estimate extracted2 studies · 43 participantsVery low
Intervention not reported
Hostility BPRS hostility sub scale, CPRS hostility subscale, Q‐sort, speech content analysis (endpoints fall between 1 and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
- no estimate extracted4 studies · 143 participantsLow
Intervention not reported
Anger Self‐reported outbursts, Rosenweig Picture Frustration Test (endpoints fall between 2 weeks and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
- no estimate extracted2 studies · 46 participantsLow
Intervention not reported
Anger‐Hostility POMS anger‐hostility subscale (endpoints fall between 1 and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
- no estimate extracted3 studies · 125 participantsLow
Intervention not reported
Non‐compliance leaving the study early (endpoints fall between 1 and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
- no estimate extracted6 studies · 411 participantsModerate